Schoeneck James A 4

What Happened

• James A. Schoeneck, a director of Kyntra Bio, received a derivative award of 7,000 shares on 2026-06-12. The award was reported at $0.00 per share (no cash paid at grant). This was an issuance/compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-12; Form filed: 2026-06-17.
• Reported acquisition: 7,000 shares at $0.00 (derivative).
• Shares owned after transaction: not specified in the filing.
• Footnote F1: "The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant."
• Filing timeliness: The Form 4 was filed on 6/17 for a 6/12 grant (appears to be filed late vs. the typical two-business-day Form 4 deadline).

Context

• This was a compensation grant subject to vesting; no immediate cash changed hands and the award will only convert to fully owned shares as it vests. Such grants are common for board compensation and do not necessarily signal a buy or sell decision by the insider.